Clearside announces additional data from CLS-AX ODYSSEY Phase 2b trial

Clearside Biomedical (CLSD) announces that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. ODYSSEY was a randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week trial evaluating CLS-AX in participants with neovascular age-related macular degeneration. The first sub-group analysis supports enrolling treatment naive patients in the planned CLS-AX Phase 3 program. The second sub-group analysis supports excluding participants prior to randomization in the Phase 3 trial who demonstrated significant non-disease related changes in visual acuity.